Methods of assessing hepatic encephalopathy
The present disclosure relates to methods of treating or ameliorating hepatic encephalopathy (HE), including assessing the severity of HE in a patient suffering from HE, or the determining the presence or occurrence of an overt hepatic encephalopathy event. In particular, some aspects of the methods use a novel Hepatic Encephalopathy Staging Tool (HEST), which includes a set of criteria to categorize the HE into different stages and provide guidance on effective treatments based on the severity of the HE. Other aspects of the methods use an Overt Hepatic Encephalopathy Screening Tool (O-HEST) to determine whether an OHE event is occurring or has occurred and provide guidance on proper medical attention and change in treatment.
1. A method of treating or ameliorating hepatic encephalopathy in a patient in need thereof, comprising:
assessing or receiving information regarding the severity of hepatic encephalopathy in the patient, wherein the severity of hepatic encephalopathy is assessed by a hepatic encephalopathy staging tool, said staging tool comprising a first criterion, a second criterion, a third criterion and a fourth criterion;
administering to the patient an effective amount of an ammonia lowering agent, wherein the ammonia lowering agent is L-ornithine phenylacetate, to treat or ameliorate hepatic encephalopathy;
wherein the first criterion comprises a first set of 4-8 factual questions designed to assess whether the patient has any disorientation, and wherein the first criterion is met when the patient verbally answers all the factual questions correctly, or when the patient verbally answers only one factual question incorrectly,
wherein the second criterion comprises a second set of 4-8 factual questions designed to assess whether the patient has any disorientation, and wherein the second criterion is met when the patient answers two or more factual questions incorrectly,
wherein the third criterion is met when at least one symptom is observed or has been observed in the patient, the symptom is selected from the group consisting of stupor, severe drowsiness, obvious confusion, and gross disorientation, wherein the fourth criterion is met when the patient is in a coma,
wherein the severity of hepatic encephalopathy in the patient is categorized into stages, wherein the first stage is defined by meeting the first criterion, the second stage is defined by meeting the second criterion, the third stage is defined by meeting the third criterion and the fourth stage is defined by meeting the fourth criterion, and
wherein the administration of the L-ornithine phenylacetate is based on the assessed severity of hepatic encephalopathy, and
assessing or receiving information regarding the severity of hepatic encephalopathy in the patient by the hepatic encephalopathy staging tool after the administration of the L-ornithine phenylacetate to determine the effectiveness of the hepatic encephalopathy treatment; and
adjusting the amount of the L-ornithine phenylacetate based on the effectiveness of the hepatic encephalopathy treatment.
2. The method of claim 1 , wherein the hepatic encephalopathy staging tool does not require observation or determination of asterixis.
3. The method of claim 1 , wherein the first set factual questions and the second set of factual questions each comprises inquiry to the patient's name, residence, birthday, time, present location, or other facts that are widely or commonly known, or combinations thereof.
4. The method of claim 3 , wherein the first set of factual questions and the second set of factual questions each comprises five to seven questions.
5. The method of claim 3 , wherein the first set of factual questions are the same as the second set of factual questions.
6. The method of claim 1 , wherein the patient is suffering from hyperammonemia, or the patient has acute liver failure, chronic liver disease, liver cirrhosis, or liver decompensation.
7. The method of claim 1 , wherein L-ornithine phenylacetate is administered orally or by intravenous infusion.
8. The method of claim 1 , wherein the first stage of hepatic encephalopathy has two sub-stages.
9. A method of treating or ameliorating hepatic encephalopathy in a patient in need thereof, comprising:
assessing or receiving information regarding the severity of hepatic encephalopathy in the patient, wherein the severity of hepatic encephalopathy is assessed by a hepatic encephalopathy staging tool, said staging tool comprising a first criterion, a second criterion, a third criterion and a fourth criterion;
administering to the patient an effective amount of an ammonia lowering agent, wherein the ammonia lowering agent is L-ornithine phenylacetate, to treat or ameliorate hepatic encephalopathy;
wherein the first criterion comprises a first set of 4-8 factual questions designed to assess whether the patient has any disorientation, and wherein the first criterion is met when the patient verbally answers all the factual questions correctly and the patient does not have asterixis,
wherein the second criterion comprises a second set of 4-8 factual questions designed to assess whether the patient has any disorientation, and wherein the second criterion is met when the patient fails to verbally answer all the factual questions correctly and the patient has asterixis,
wherein the third criterion is met when at least one symptom is observed or has been observed in the patient, the symptom is selected from the group consisting of stupor, severe drowsiness, obvious confusion, and gross disorientation,
wherein the fourth criterion is met when the patient is in a coma,
wherein the severity of hepatic encephalopathy in the patient is categorized into stages, wherein the first stage is defined by meeting the first criterion, the second stage is defined by meeting the second criterion, the third stage is defined by meeting the third criterion and the fourth stage is defined by meeting the fourth criterion,
wherein the administration of the L-ornithine phenylacetate is based on the assessed severity of hepatic encephalopathy, and
assessing or receiving information regarding the severity of hepatic encephalopathy in the patient by the hepatic encephalopathy staging tool after the administration of the L-ornithine phenylacetate to determine the effectiveness of the hepatic encephalopathy treatment; and
adjusting the amount of the L-ornithine phenylacetate based on the effectiveness of the hepatic encephalopathy treatment.
10. The method of claim 9 , wherein the first stage of hepatic encephalopathy has two sub-stages.
11. The method of claim 9 , wherein the first set factual questions and the second set of factual questions each comprises inquiry to the patient's name, residence, birthday, time, present location, or other facts that are widely or commonly known, or combinations thereof.
12. The method of claim 11 , wherein the first set of factual questions and the second set of factual questions each comprises five to seven questions.
13. The method of claim 11 , wherein the first set of factual questions are the same as the second set of factual questions.
14. The method of claim 9 , wherein the patient is suffering from hyperammonemia, or the patient has acute liver failure, chronic liver disease, liver cirrhosis, or liver decompensation.
15. The method of claim 9 , wherein L-ornithine phenylacetate is administered orally or by intravenous infusion.